Comments on: Immunopheotype of Gastrointestinal stromal tumours (GIST) http://pathtalk.org/archives/1196 is a weblog about pathology and laboratory medicine. Tue, 24 Apr 2012 10:23:45 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: PathDoc15 http://pathtalk.org/archives/1196/comment-page-1#comment-1199 PathDoc15 Mon, 13 Jul 2009 12:32:14 +0000 http://pathtalk.org/?p=1196#comment-1199 Excellent summary - It is interesting that in other tumor types (melanoma for example), CKIT IHC is a very poor surogate for mutation status of CKIT. Is it a perfect corelate in GIST? I remember a recent trial showing that patients with GISTs that harbor specific mutations in CKIT (I can't remember which) responded better to imatinib dose escallation. Is there a role for mutation analysis in the management of GIST? Thanks for the post! Excellent summary – It is interesting that in other tumor types (melanoma for example), CKIT IHC is a very poor surogate for mutation status of CKIT. Is it a perfect corelate in GIST?

I remember a recent trial showing that patients with GISTs that harbor specific mutations in CKIT (I can’t remember which) responded better to imatinib dose escallation. Is there a role for mutation analysis in the management of GIST?

Thanks for the post!

]]> By: P.Das http://pathtalk.org/archives/1196/comment-page-1#comment-1192 P.Das Thu, 09 Jul 2009 02:58:56 +0000 http://pathtalk.org/?p=1196#comment-1192 Excellent post.Thanks Excellent post.Thanks

]]>